TAMPA, FL – December 2, 2025 (NEWMEDIAWIRE) – Dear Shareholders,
I want to begin by thanking you for your support and investment in CTT. I believe we are beginning a period of great opportunity and growth. Our patented micelle thin-film technology positions CTT to be a unique and powerful force in the drug delivery industry, offering better, faster, and more convenient oral drug delivery options. My immediate focus as CEO will be to bring micelle encapsulated vitamins and other bioactive supplement strips, as well as nicotine oral strips into manufacturing in 2026. We are in the final stages of preparing an S-1 that will enable the company to access funding from the equity line and will make us a SEC reporting company. A news release will be sent out to shareholders as we get closer to filing the S-1. Being SEC reporting is an important step for the company as it will bring additional transparency and potentially a larger group of shareholders and investors to CTT Pharma. We hope to be SEC Reporting before the end of 2025 but understand it could happen towards the beginning of Q1 2026. The capital from this ELOC will be used towards manufacturing of our patented technology. I want shareholders to know that I have been be very mindful of our share count and dilution and will continue to do so in the future.
CTT is currently in the process of strengthening our team with regulatory experts who can assist us in moving our patented technology through the required approval process for sales in North America. Additionally, I am also planning to bring on an additional person to our team who has extensive experience in bringing commercial products to market.
We are in the process of locating a facility for manufacturing. I anticipate identifying a building in the first quarter and from there we will acquire the equipment needed for production.
Additionally, our partnership with Johns Hopkins University, as part of the NIH grant utilizing our technology as a smoking cessation alternative, is still awaiting a funding decision for clinical trials. I will update shareholders immediately once we receive any new information. It is important to note that our manufacturing and commercialization plans are not dependent on the timing of this NIH decision.
Recently, one of our scientists, Dr. Katharine Cole, together with Dr. Pankaj Modi, the founder of CTT, submitted a scholarly review manuscript to a scientific journal for peer review and potential publication. This paper provides a comprehensive review of the current research in micelle/oral dissolvable strip technology. We just received feedback from the journal’s peer-review committee, and the manuscript has been accepted for publication on December 15, 2025. This publication will assist us in increasing visibility and understanding of the scientific principles that underlie our micelle oral dissolvable strip platform. We believe this will be a positive step in educating and engaging shareholders, potential companies that have an interest in partnering with us, as well as the wider scientific and public communities. The publication will be sent to shareholders after the publication date next month through a news release. Additionally, I’m looking to schedule a conference call in the first quarter to discuss CTT’s progress and our upcoming initiatives.
Finally, I have been working to strengthen our patent portfolio and will share additional information on these patents as more information develops.
Thank you again for your support and trust in CTT’s vision. With capital now in place, we are expanding our team, moving towards manufacturing, and defining the regulatory paths to commercialization. I look forward to providing additional information soon.
Sincerely,
Ryan Khouri
12/2/25
813-606-0060
(OTCQB-CTTH)
View the original release on www.newmediawire.com